Stamoulis Christiana 4

What Happened
Christiana Stamoulis, President and Chief Financial Officer of Keenova Therapeutics plc, was granted 101,262 restricted stock units (RSUs) on February 25, 2026. The RSUs were reported as a derivative award at $0.00 per unit (no cash exchanged at grant). These RSUs will convert into ordinary shares on vesting; there is no immediate share ownership change or sale.

Key Details

• Transaction type: Award/Grant of RSUs (derivative) reported on Form 4 (code A).
• Grant date: February 25, 2026; filing date: February 26, 2026 (filed promptly the next day).
• Number of RSUs: 101,262; reported acquisition price: $0.00 (grant value at issuance not listed).
• Vesting/settlement (footnotes): Each RSU settles 1-for-1 into ordinary shares upon vesting. RSUs vest ratably on each of the first three anniversaries of February 25, 2027 (roughly one-third vesting each year).
• Shares owned after transaction: Not specified in the provided filing summary.
• Additional note: The Form 4 also serves as notice to the issuer under Part V of the Companies Act 2014.

Context
RSU grants are compensation awards that convert into company stock only when they vest; they are not purchases and do not represent immediate cash proceeds. For retail investors, RSU grants signal management compensation alignment with shareholders but are routine corporate governance actions and not definitive statements about short-term market views.